دورية أكاديمية
A rapid review of differences in cerebrospinal neurofilament light levels in clinical subtypes of progressive multiple sclerosis.
| العنوان: | A rapid review of differences in cerebrospinal neurofilament light levels in clinical subtypes of progressive multiple sclerosis. |
|---|---|
| المؤلفون: | Desu HL; Neuroimmunology Unit, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.; Department of Neurosciences, Université de Montréal, Montreal, QC, Canada., Sawicka KM; Child Health Evaluative Sciences Program, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada.; Department of Medicine, Division of Neurology, University of Toronto, Toronto, ON, Canada.; Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada., Wuerch E; Hotchkiss Brain Institute and the Department of Clinical Neuroscience, University of Calgary, Calgary, AB, Canada., Kitchin V; University of British Columbia Library, Vancouver, BC, Canada., Quandt JA; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.; Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada. |
| المصدر: | Frontiers in neurology [Front Neurol] 2024 Apr 09; Vol. 15, pp. 1382468. Date of Electronic Publication: 2024 Apr 09 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101546899 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2295 (Print) Linking ISSN: 16642295 NLM ISO Abbreviation: Front Neurol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation, 2010]- |
| مستخلص: | Background: Multiple sclerosis (MS) is divided into three clinical phenotypes: relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS). It is unknown to what extent SPMS and PPMS pathophysiology share inflammatory or neurodegenerative pathological processes. Cerebrospinal (CSF) neurofilament light (NfL) has been broadly studied in different MS phenotypes and is a candidate biomarker for comparing MS subtypes. Research Question: Are CSF NfL levels different among clinical subtypes of progressive MS? Methods: A search strategy identifying original research investigating fluid neurodegenerative biomarkers in progressive forms of MS between 2010 and 2022 was applied to Medline. Identified articles underwent title and abstract screen and full text review against pre-specified criteria. Data abstraction was limited to studies that measured NfL levels in the CSF. Reported statistical comparisons of NfL levels between clinical phenotypes were abstracted qualitatively. Results: 18 studies that focused on investigating direct comparisons of CSF NfL from people with MS were included in the final report. We found NfL levels were typically reported to be higher in relapsing and progressive MS compared to healthy controls. Notably, higher NfL levels were not clearly associated with progressive MS subtypes when compared to relapsing MS, and there was no observed difference in NfL levels between PPMS and SPMS in articles that separately assessed these phenotypes. Conclusion: CSF NfL levels distinguish individuals with MS from healthy controls but do not differentiate MS subtypes. Broad biological phenotyping is needed to overcome limitations of current clinical phenotyping and improve biomarker translatability to decision-making in the clinic. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Desu, Sawicka, Wuerch, Kitchin and Quandt.) |
| References: | Ann Neurol. 2001 Sep;50(3):389-400. (PMID: 11558796) J Magn Reson Imaging. 2019 Sep;50(3):878-888. (PMID: 30652391) J Clin Epidemiol. 2021 Feb;130:13-22. (PMID: 33068715) Brain. 2002 Feb;125(Pt 2):327-37. (PMID: 11844733) JAMA Neurol. 2021 Mar 1;78(3):351-364. (PMID: 33315071) Mult Scler Relat Disord. 2021 Jan;47:102666. (PMID: 33291033) Nat Rev Dis Primers. 2018 Nov 8;4(1):43. (PMID: 30410033) Front Immunol. 2021 Dec 07;12:753929. (PMID: 34950135) Front Neurol. 2018 Dec 18;9:1075. (PMID: 30619038) Neurol Neuroimmunol Neuroinflamm. 2022 May 9;9(4):. (PMID: 35534236) Neurol Clin Pract. 2021 Aug;11(4):342-351. (PMID: 34476126) Science. 2015 Jan 23;347(6220):1260419. (PMID: 25613900) Ann Clin Transl Neurol. 2020 Dec;7(12):2508-2523. (PMID: 33146954) Neuroimaging Clin N Am. 2017 May;27(2):277-287. (PMID: 28391786) Sci Rep. 2020 Jun 25;10(1):10381. (PMID: 32587320) J Neurol. 2021 Sep;268(9):3212-3222. (PMID: 32447549) Lancet. 2018 Mar 31;391(10127):1263-1273. (PMID: 29576505) Lancet Neurol. 2023 Jan;22(1):78-88. (PMID: 36410373) Neurol Neuroimmunol Neuroinflamm. 2021 Mar 3;8(3):. (PMID: 33658322) PLoS One. 2022 Sep 14;17(9):e0274565. (PMID: 36103562) Mult Scler. 2021 Jun;27(7):1002-1004. (PMID: 33874813) Neurology. 2021 Aug 24;97(8):378-388. (PMID: 34088878) Mult Scler Relat Disord. 2022 Jan;57:103409. (PMID: 34871856) J Int Med Res. 2019 May;47(5):2187-2198. (PMID: 30982375) Mult Scler. 2017 Nov;23(13):1727-1735. (PMID: 28831853) Ann Neurol. 2010 Oct;68(4):477-93. (PMID: 20976767) Nat Rev Neurol. 2023 Aug;19(8):461-476. (PMID: 37400550) Neurol Neuroimmunol Neuroinflamm. 2020 Nov 10;8(1):. (PMID: 33172960) N Engl J Med. 1998 Jan 29;338(5):278-85. (PMID: 9445407) Mult Scler. 2023 Oct;29(11-12):1363-1372. (PMID: 37691493) Trends Neurosci. 2016 May;39(5):325-339. (PMID: 26987259) Clin Chem Lab Med. 2016 Oct 1;54(10):1655-61. (PMID: 27071153) Neurol Neuroimmunol Neuroinflamm. 2022 Nov 14;10(1):. (PMID: 36376097) J Neurochem. 2018 Aug;146(3):322-332. (PMID: 29676479) Mult Scler. 2014 Jan;20(1):43-50. (PMID: 23702432) Mult Scler Relat Disord. 2022 Jul;63:103922. (PMID: 35671674) Rev Neurosci. 2021 Feb 17;32(6):573-595. (PMID: 33594840) J Neuroimmunol. 2016 Oct 15;299:112-117. (PMID: 27725108) Front Neurosci. 2021 Apr 06;15:642384. (PMID: 33889068) Acta Neuropathol. 2012 May;123(5):627-38. (PMID: 22327362) Neurology. 2014 Jul 15;83(3):278-86. (PMID: 24871874) JAMA Neurol. 2021 May 1;78(5):558-567. (PMID: 33779698) Biomedicines. 2022 Mar 24;10(4):. (PMID: 35453510) Brain. 2017 Mar 1;140(3):527-546. (PMID: 27794524) Mult Scler. 2013 Oct;19(12):1597-603. (PMID: 23529999) N Engl J Med. 2010 Feb 4;362(5):416-26. (PMID: 20089960) Brain. 2009 May;132(Pt 5):1175-89. (PMID: 19339255) JAMA Neurol. 2020 Sep 1;77(9):1132-1140. (PMID: 32511687) Neurol Neuroimmunol Neuroinflamm. 2022 Mar 3;9(3):. (PMID: 35241571) N Engl J Med. 2020 Aug 6;383(6):546-557. (PMID: 32757523) Neurol Neuroimmunol Neuroinflamm. 2022 Aug 30;9(6):. (PMID: 36041861) J Neurol Neurosurg Psychiatry. 2019 Sep;90(9):1059-1067. (PMID: 31123141) J Intern Med. 2021 Aug;290(2):473-476. (PMID: 33871105) Neurol Sci. 2013 Feb;34(2):181-6. (PMID: 22362332) Brain. 2005 Nov;128(Pt 11):2705-12. (PMID: 16230320) Front Neurol. 2021 Nov 29;12:782599. (PMID: 34912290) Sci Rep. 2018 Oct 4;8(1):14798. (PMID: 30287870) Mult Scler Relat Disord. 2021 Nov;56:103269. (PMID: 34638097) Mult Scler Relat Disord. 2021 Jun;51:102861. (PMID: 33773271) Mult Scler. 2013 Mar;19(3):268-9. (PMID: 23426170) Nat Rev Neurol. 2022 Jan;18(1):40-55. (PMID: 34732831) JAMA Neurol. 2020 Jan 1;77(1):58-64. (PMID: 31515562) Mult Scler Relat Disord. 2019 May;30:149-153. (PMID: 30772673) J Neurol. 2014 Dec;261(12):2338-43. (PMID: 25228004) Brain Commun. 2021 Oct 12;3(4):fcab240. (PMID: 34755110) Nat Rev Neurol. 2022 Mar;18(3):158-172. (PMID: 35115728) Neurology. 2009 Jun 2;72(22):1914-21. (PMID: 19487649) Bioanalysis. 2019 Aug;11(15):1405-1418. (PMID: 31401845) J Neuroimaging. 2020 May;30(3):251-266. (PMID: 32418324) Neurology. 2020 Sep 8;95(10):436-444. (PMID: 32675076) Brain. 2021 Nov 29;144(10):2954-2963. (PMID: 34180982) J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-881. (PMID: 30967444) J Proteome Res. 2023 Mar 3;22(3):743-757. (PMID: 36720471) Front Neurol. 2018 Dec 14;9:1037. (PMID: 30631300) |
| فهرسة مساهمة: | Keywords: biomarkers; multiple sclerosis; neurodegeneration; neurofilament light; progression |
| تواريخ الأحداث: | Date Created: 20240424 Latest Revision: 20240426 |
| رمز التحديث: | 20240426 |
| مُعرف محوري في PubMed: | PMC11035744 |
| DOI: | 10.3389/fneur.2024.1382468 |
| PMID: | 38654736 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-2295 |
|---|---|
| DOI: | 10.3389/fneur.2024.1382468 |